A PROPOSED BIOMARKER: LIVER TUMOR VOLUME ESTIMATION

- Similar to Biomarkers for Other Modalities
- Clinically Important – Examples HCC, CRC
  - 1.2 million new CRC cases/yr. (USA 137k/yr.) about 50% will develop liver metastases
  - 560k new HCC cases/yr. (USA 36k/yr.)
- Size Estimates Needed to Monitor Tumor Progression and Response to Therapy
Spatial Volume measurements
LIVER TUMOR VOLUME IMPACT & FEASIBILITY

- Reliable US Measurement Would Lower Costs Compared to CT and MRI
- The ONLY Option for Resource Poor Countries Worldwide
- Methodologies Developed Could be Easily Extended to Other Organs—kidney, cardiac, uterine, thyroid, IMT
- Feasible: The Methods are Known & Just Need Refining & Standardization